65,437 trials
Coronary Artery Chronic Total Occlusion
Primary: Technical Success — 77 percentage of CTOs
Acute Coronary Syndrome
Primary: Participants With Any Event From the Composite of Death From Vascular Causes, Myocardial Infarction (MI), and Stroke — 864; 1014 Participants
Bilateral Nasolabial Fold Wrinkles
Primary: Subject Wrinkle Assessment Responders — 50; 19 participants — p=<.00001
Essential Hypertension
Primary: Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure. — -37.6; -38.2; -31.5 mmHg — p=<0.001
Osteoporosis · Osteopenia
Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL
Chronic Kidney Failure · Secondary Hyperparathyroidism
Primary: Safety Evaluation of Paricalcitol by Recording the Number of Hospitalizations — 152; 85; 59; 16 participants
Carcinoid Tumor · Malignant Carcinoid Syndrome
Primary: Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review — 16.43; 11.33 Months
Sarcoma
Primary: Objective Response Rate — 6; 5; 14 participants
Stoma
Primary: Quality of Life (Scale 0(Worst)-100(Best)) — 1.8 units on a scale — p=<0.0001
Breast Neoplasm
Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Head and Neck Cancer
Primary: Patient Response to Treatment Measured by RECIST Criteria — 1; 18; 19; 2 participants
Hypercholesterolemia
Primary: Percentage Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Concentration After 6 Weeks of Treatment Comparing Rosuvastatin 5mg With Atorvastatin 10mg…
Type 2 Diabetes Mellitus · Depression
Primary: Hemoglobin A1C — 60.9; 35.7 Percentage of participants with HbA1c <7
Nocturia · Prostatic Hyperplasia
Primary: Change in Nocturia Episodes — -1.2; -1.0 episodes
Depression
Primary: Change in Cognitive Status as Measured by the Children's Auditory Verbal Learning Test 2 (CAVLT-2) — -11.3 units on a scale